MHRA authorize Lilly’s orforglipron tablet for weight management and T2 diabetes, but NHS access still hinges on a NICE decision yet to come.
First across the line, not necessarily first to reach patients. On 10 August, the Medicines and Healthcare products Regulatory Agency (MHRA) authorized orforglipron, sold as Foundayo, making the UK the first country in Europe, and the first regulator anywhere, to approve an oral GLP-1 receptor agonist for both weight management and type 2 diabetes [1].
The approval lands ahead of decisions from the European Medicines Agency and the US Food and Drug Administration (FDA), both of which are still reviewing Eli Lilly’s application. For a drug category that has so far meant weekly injections, a same-class pill clearing a major regulator first is a milestone worth pausing on, even before the question of who can get it.
Orforglipron is authorized, alongside a reduced-calorie diet and increased physical activity, for weight loss and weight maintenance in adults with a BMI of 30 or above, or a BMI between 27 and 30 plus at least one weight-related comorbidity. It is separately authorized to improve glycemic control in adults with insufficiently controlled type 2 diabetes.
Dosing starts at 0.8 mg once daily, escalating in six steps up to 17.2 mg, with a minimum of one month at each level before the next increase, and the tablet can be taken at any time of day without food or water restrictions.
“Following rigorous assessment of orforglipron’s safety, quality, and effectiveness, we are pleased to be the first regulator in Europe to authorise this tablet for weight management and type 2 diabetes,” said Julian Beach, MHRA Executive Director of Healthcare Quality and Access. “As with all GLP-1 receptor agonists, this is a prescription-only medication, and the MHRA will keep the safety and effectiveness of orforglipron under close review.”
Why a pill changes the calculus
Every GLP-1 receptor agonist approved to date, semaglutide included, has required subcutaneous injection, a manufacturing and delivery constraint that has contributed directly to the supply shortages seen across the category since 2023.
Orforglipron works the same way pharmacologically, mimicking the GLP-1 hormone the body releases after eating to reduce appetite and support glycaemic control, but as a small molecule rather than a peptide, it can be manufactured using standard oral tablet processes instead of the more complex, capacity-constrained processes injectable peptides require. That distinction matters less for any single patient’s experience than it does for the category’s supply chain as a whole: a class of medicines that has struggled to meet global demand may finally have a manufacturing pathway capable of catching up.
The gap between approval and access
Authorization is not the same as availability, and the MHRA is explicit about that gap in its own release. Orforglipron is not currently available through the NHS, and decisions on NHS use will follow the standard evaluation process through the National Institute for Health and Care Excellence (NICE), which assesses cost-effectiveness before recommending public funding for a new medicine.
In practice, that means a UK patient today can only access orforglipron through a private prescription, a two-tier access pattern that has already played out with injectable GLP-1s, where NHS rollout for weight management lagged private availability by a considerable margin. The MHRA’s approval is a genuine regulatory first, but the more consequential date, for most UK patients, is whichever one NICE eventually attaches to its guidance.
The enforcement problem regulators keep flagging
The MHRA release also repeats a warning it has issued before: GLP-1 medicines are prescription-only, obtainable solely through a registered pharmacy with a doctor’s prescription, and promoting any prescription-only medicine directly to the public is against the law in the UK. Buying GLP-1 drugs from unregulated sellers, the agency notes, carries serious health risks, an issue that has grown alongside demand for this drug class rather than shrunk.
A widely available oral formulation, easier to counterfeit and easier to sell online without obvious red flags than an injectable pen, arguably raises the stakes on that enforcement problem rather than resolving it.
Patients experiencing side effects, most commonly nausea, constipation, diarrhea, vomiting, indigestion and abdominal pain, are directed to report them through the UK’s Yellow Card scheme, either online or via the MHRA Yellow Card app.
What to watch next
Three things will determine whether the UK’s first-mover status translates into a meaningfully different market. The first is timing: how quickly the EMA and FDA follow with their own authorisations, and whether either regulator requires additional data that the MHRA did not. The second is NICE’s eventual cost-effectiveness verdict, which will decide whether orforglipron becomes an NHS-funded option or remains a private-pay drug for the UK market, as many injectable GLP-1s effectively still are. The third is manufacturing: whether Eli Lilly can actually scale oral production fast enough to relieve the supply pressure that has defined this drug class since it went mainstream, or whether demand simply outpaces a new format the same way it outpaced the old one. The regulatory race has a winner. The access race is still open.
